Endo International plc (ENDP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Endo International plc (ENDP) trades at $0.37 with AI Score 47/100 (Grade C). Endo International plc is a specialty pharmaceutical company manufacturing and selling generic and branded pharmaceuticals. Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for ENDP: ENDP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENDP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENDP: the 1 perspectives are evenly split.
How is this calculated? →Endo International plc (ENDP) Healthcare & Pipeline Overview
Endo International plc, based in Dublin, focuses on developing, manufacturing, and distributing specialty and generic pharmaceuticals. The company operates through branded pharmaceuticals, sterile injectables, generic pharmaceuticals, and international pharmaceuticals segments. Currently navigating Chapter 11 reorganization, Endo aims to restructure its debt and operations amidst a competitive landscape.
What Is the Investment Thesis for ENDP?
Endo International plc faces significant challenges due to its Chapter 11 bankruptcy filing in 2022. The company's future hinges on successful restructuring and debt reduction. Key value drivers include the performance of its Branded Pharmaceuticals segment, particularly products like XIAFLEX and QWO. The Sterile Injectables segment also contributes significantly to revenue. However, the company's negative profit margin of -19.0% and ongoing legal and financial challenges pose substantial risks. Successful navigation of the bankruptcy process and strategic product portfolio management are critical for long-term viability. Investors should closely monitor the restructuring progress and any potential catalysts arising from new product launches or market expansions.
Based on FMP financials and quantitative analysis
ENDP Key Highlights
- Endo International plc filed for Chapter 11 bankruptcy on August 16, 2022, indicating significant financial distress.
- The company's gross margin stands at 59.2%, reflecting the potential profitability of its products before operating expenses and debt obligations.
- Endo operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals, diversifying its revenue streams.
- Key branded products include XIAFLEX, SUPPRELIN LA, and QWO, targeting specific medical conditions and patient populations.
- The company's beta of 1.15 suggests a slightly higher volatility compared to the overall market.
Who Are ENDP's Competitors?
ENDP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries Limited | $35.29 | +1.88% | $41.09B | 44 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENDP's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Established presence in both branded and generic pharmaceuticals.
- Manufacturing capabilities for sterile injectables.
- Global distribution network.
What Are ENDP's Weaknesses?
- High debt levels and ongoing bankruptcy proceedings.
- Negative profit margin.
- Exposure to litigation and regulatory risks.
- Dependence on key products for revenue.
What Could Drive ENDP Stock Higher?
- Successful completion of Chapter 11 bankruptcy proceedings and debt restructuring.
- Potential new product launches in the Branded Pharmaceuticals segment.
- Positive clinical trial results for pipeline products.
- Expansion into new geographic markets.
What Are the Key Risks for ENDP?
- High debt levels and financial instability.
- Litigation and regulatory challenges.
- Intense competition from other pharmaceutical companies.
- Pricing pressures and generic erosion.
- Negative impact of economic downturns on healthcare spending.
What Are the Growth Opportunities for ENDP?
- Expansion of QWO Market: QWO, an injectable treatment for cellulite, represents a significant growth opportunity for Endo. The market for aesthetic treatments is expanding, with increasing consumer demand for non-invasive procedures. Successful marketing and distribution of QWO, coupled with positive clinical outcomes, could drive substantial revenue growth. The global cellulite treatment market is projected to reach billions of dollars, offering a considerable addressable market for Endo.
- Sterile Injectables Segment Growth: The Sterile Injectables segment, featuring products like VASOSTRICT and ADRENALIN, offers growth potential through increased demand for critical care medications. Expansion into new geographic markets and the development of new injectable products could further drive growth. The global sterile injectables market is expected to grow, driven by the increasing prevalence of chronic diseases and the need for acute care treatments.
- International Market Expansion: Endo's International Pharmaceuticals segment provides an opportunity to expand its presence in key markets. Focusing on specific therapeutic areas, such as pain management and women's health, and tailoring products to local market needs could drive growth. Emerging markets, in particular, offer significant potential for pharmaceutical companies.
- Strategic Partnerships and Acquisitions: Endo could pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring complementary businesses could enhance its competitive position and drive revenue growth. Identifying and integrating synergistic assets will be crucial for success.
- Generic Pharmaceuticals Portfolio Optimization: Endo's Generic Pharmaceuticals segment can be optimized by focusing on high-value products and streamlining operations. Identifying and divesting non-core assets, while investing in the development and launch of new generic drugs, could improve profitability. The generic drug market remains a significant opportunity, driven by patent expirations and cost-containment pressures.
What Opportunities Does ENDP Have?
- Expansion of QWO market.
- Growth in sterile injectables segment.
- Strategic partnerships and acquisitions.
- International market expansion.
What Threats Does ENDP Face?
- Intense competition from other pharmaceutical companies.
- Pricing pressures and generic erosion.
- Regulatory changes and patent expirations.
- Economic downturns affecting healthcare spending.
What Are ENDP's Competitive Advantages?
- Proprietary formulations and patent protection for branded products.
- Established relationships with healthcare providers and distributors.
- Manufacturing capabilities for sterile injectables.
- Diverse product portfolio across multiple therapeutic areas.
What Does ENDP Do?
Founded in 1920, Endo International plc has evolved into a global specialty pharmaceutical company. Headquartered in Dublin, Ireland, Endo develops, manufactures, and distributes a range of branded and generic pharmaceutical products. The company operates through four primary segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products like XIAFLEX for Dupuytren's contracture, SUPPRELIN LA for central precocious puberty, and QWO for cellulite treatment. The Sterile Injectables segment provides VASOSTRICT and ADRENALIN, among other injectable products. The Generic Pharmaceuticals segment includes solid oral extended-release and immediate-release products, liquids, and semi-solids. The International Pharmaceuticals segment focuses on specialty products in areas like ADHD, pain management, and women's health. Endo markets its products to various customers, including specialty physicians, retailers, clinics, government agencies, and pharmacies. On August 16, 2022, Endo filed for Chapter 11 bankruptcy, seeking to reorganize its business and address its debt obligations. The company is currently working through this process to restructure its operations and financial position.
What Products and Services Does ENDP Offer?
- Develops and manufactures branded pharmaceutical products.
- Produces and sells generic pharmaceutical products.
- Offers sterile injectable medications.
- Markets products internationally in various therapeutic areas.
- Provides treatments for conditions like Dupuytren's contracture and cellulite.
- Sells products to specialty physicians, retailers, and pharmacies.
How Does ENDP Make Money?
- Develops and commercializes branded pharmaceuticals with patent protection.
- Manufactures and distributes generic drugs after patents expire.
- Sells sterile injectable products to hospitals and clinics.
- Generates revenue through product sales to various customer segments.
What Industry Does ENDP Operate In?
Endo International plc operates within the specialty and generic pharmaceutical industry, a sector characterized by intense competition, regulatory scrutiny, and pricing pressures. The market includes both branded and generic drug manufacturers, each with distinct business models and challenges. Key trends include the increasing demand for generic drugs, the rise of biosimilars, and the growing focus on specialty pharmaceuticals targeting specific diseases. Endo's bankruptcy reflects the financial challenges faced by some companies in this industry, particularly those burdened by debt and litigation. Competitors range from large multinational corporations to smaller, specialized firms.
Who Are ENDP's Key Customers?
- Specialty physicians
- Retail and specialty pharmacies
- Hospitals and clinics
- Government agencies
- Patients
Endo International plc (ENDP) Valuation Context
Relative to its peer group, ENDP's quantitative score of 47/100 is below the peer average of 63/100.
ROE 60%Key Financial Metrics
Return on equity for Endo International plc stands at 60.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.5%, showing how much profit it generates from its asset base. A current ratio of 1.67 indicates the company holds enough short-term assets to cover its near-term obligations.
ENDP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Endo's recent restructuring efforts might finally stabilize the ship. Could be a turnaround play if they manage debt effectively.
- The opioid litigation overhang seems to be priced in. Any positive legal news could trigger a significant relief rally.
- Despite the challenges, Endo still possesses a portfolio of established products that generate revenue. There's inherent value there.
- Some community members are betting on a short squeeze. High short interest could lead to rapid gains if positive catalysts emerge.
Bear Case
- Endo's debt load remains a massive concern. It's a constant drag on the company's prospects and limits their flexibility.
- The opioid litigation risk hasn't completely disappeared. Further legal setbacks could severely impact the company's financial health.
- Community sentiment is largely negative, reflecting deep skepticism about Endo's long-term viability. This pessimism can be self-fulfilling.
- The generic drug market is fiercely competitive. Endo faces constant pressure to maintain market share and profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ENDP Latest News
-
This Technology Stock is Down By Over 11%: Here's 26 Stocks Moving Premarket
benzinga · Jul 5, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jun 13, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
-
Earnings Scheduled For May 5, 2022
benzinga · May 5, 2022
ENDP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENDP.
Price Targets
Wall Street price target analysis for ENDP.
ENDP MoonshotScore
What does this score mean?
The MoonshotScore rates ENDP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Blaise Coleman
CEO
Blaise Coleman serves as the CEO of Endo International plc. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic leadership and operational management. Prior to becoming CEO, he held various leadership positions within Endo, contributing to the company's strategic direction and growth initiatives. Coleman's expertise spans across multiple functional areas, including finance, operations, and commercial strategy. He is responsible for guiding Endo through its restructuring process and charting a path for future success.
Track Record: Since becoming CEO, Blaise Coleman has focused on navigating Endo through its Chapter 11 bankruptcy proceedings and developing a restructuring plan. Key initiatives include optimizing the company's product portfolio, reducing debt, and improving operational efficiency. His leadership is crucial for securing the company's long-term viability and restoring stakeholder confidence.
What Investors Ask About Endo International plc (ENDP) — Healthcare
What does Endo International plc do?
Endo International plc is a specialty pharmaceutical company that develops, manufactures, and sells a range of branded and generic pharmaceutical products. The company operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its key products include XIAFLEX, SUPPRELIN LA, QWO, VASOSTRICT, and various generic medications. Endo markets its products to specialty physicians, retailers, pharmacies, and other healthcare providers. The company is currently undergoing Chapter 11 bankruptcy proceedings to restructure its debt and operations.
What do analysts say about ENDP stock?
Given Endo International plc's Chapter 11 bankruptcy filing, traditional analyst ratings and price targets may not be readily available or reliable. The company's stock performance is highly dependent on the outcome of the restructuring process and the successful implementation of its reorganization plan. Investors should focus on monitoring the company's progress in reducing debt, optimizing its product portfolio, and improving operational efficiency. Key valuation metrics may be less relevant during this period of uncertainty.
What are the main risks for ENDP?
Endo International plc faces several significant risks, primarily related to its financial condition and ongoing bankruptcy proceedings. High debt levels, litigation exposure, and intense competition in the pharmaceutical industry pose substantial challenges. The company's ability to successfully restructure its debt, optimize its product portfolio, and navigate regulatory hurdles will be critical for its long-term viability. Negative impacts from economic downturns and pricing pressures in the generic drug market also represent potential risks.
How does Endo International plc manage patent expiration risks?
Endo International plc manages patent expiration risks through a combination of strategies, including developing new formulations, pursuing patent extensions, and launching authorized generics. The company also focuses on diversifying its product portfolio to reduce dependence on any single product or therapeutic area. Strategic acquisitions and partnerships can further mitigate patent expiration risks by adding new products and technologies to the pipeline. Lifecycle management strategies are crucial for maintaining revenue streams and extending the commercial life of key products.
What is Endo International plc's drug pipeline status?
Endo International plc's drug pipeline includes several products in various stages of development, targeting specific therapeutic areas such as pain management, urology, and aesthetics. The company's pipeline focuses on developing innovative formulations and delivery systems to improve patient outcomes and address unmet medical needs. Clinical trial results and regulatory approvals represent key catalysts for pipeline products. Investors should monitor the progress of these pipeline products, as successful launches could drive future revenue growth and enhance the company's competitive position.
What are the key factors to evaluate for ENDP?
Endo International plc (ENDP) holds an AI score of 47/100 (low). Not financial advice.
How frequently does ENDP data refresh on this page?
ENDP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ENDP's recent stock price performance?
Endo International plc (ENDP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available public data and may be subject to change.
- The company is currently undergoing Chapter 11 bankruptcy proceedings, which introduces significant uncertainty.